Nickan Research Institute Journal of Renal Endocrinology 2423-6438 10 1 2024 01 01 Effects of ACE inhibitors/ARBs on lung cancer; an updated mini-review on recent data e25175 e25175 10.34172/jre.2024.25175 EN Zahra Golestani Hotkani https://orcid.org/0000-0001-8929-0208 Tella Sadighpour https://orcid.org/0000-0002-3131-3339 Ali Shirbacheh https://orcid.org/0000-0001-5334-0736 Kamran Shirbache https://orcid.org/0000-0002-9042-9534 Journal Article 10.34172/jre.2024.25175 2024 09 20 2024 11 05 Several observational studies have indicated a potential protective effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) against lung cancer. These investigations have demonstrated a reduced risk of lung cancer among individuals utilizing ACEIs or ARBs compared to those not receiving these medications. However, it is crucial to acknowledge that observational studies cannot establish a cause-and-effect relationship, as other confounding factors may be at play. Conversely, conflicting outcomes have been reported in certain studies, revealing no discernible association between ACEIs/ARBs and the risk of lung cancer. Furthermore, limited evidence from randomized controlled trials specifically designed to investigate this relationship exists. It is imperative to recognize that these trials have inherent limitations, including potential biases and confounding factors. Therefore, additional research is essential to ascertain a definitive connection between ACEIs/ARBs and lung cancer. This review seeks to assess the available data and explore potential mechanisms underlying this association.